Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Aug 27, 2024; 16(8): 2555-2564
Published online Aug 27, 2024. doi: 10.4240/wjgs.v16.i8.2555
Published online Aug 27, 2024. doi: 10.4240/wjgs.v16.i8.2555
Transmembrane serine protease 4 expression in the prognosis of radical resection for biliary tract cancer
Yoshiyuki Shibata, Takeshi Sudo, Sho Tazuma, Naoki Tanimine, Takashi Onoe, Yosuke Shimizu, Hirotaka Tashiro, Department of Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima 737-0023, Japan
Atsushi Yamaguchi, Department of Gastroenterology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima 737-0023, Japan
Kazuya Kuraoka, Department of Diagnostic Pathology, National Hospital Organization Kure Medical Center, and Chugoku Cancer Center, Hiroshima 737-0023, Japan
Shinya Takahashi, Department of Surgery, Graduate School of Biochemical and Health Science, Hiroshima University, Hiroshima 734-8551, Japan
Author contributions: Shibata Y and Sudo T performed the study conception and design, data acquisition, data analysis and interpretation, drafting of the manuscript, and critical revision of the manuscript; Tazuma S, Tanimine N, Onoe T, Shimizu Y, Yamaguchi A and Tashiro H performed the data acquisition; Kuraoka K performed the data acquisition and the data analysis and interpretation; Takahashi S critically revised the manuscript.
Institutional review board statement: The protocol for this research project has been approved by a suitably constituted Ethics Committee of the institution, and it conforms to the provisions of the Declaration of Helsinki. The Institutional Review Board of National Hospital Organization Kure Medical Center approved this study (Approval No. 2023-45 on October 4, 2023).
Informed consent statement: All patients provided written informed consent.
Conflict-of-interest statement: The authors have no financial relationships to disclose.
Data sharing statement: The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yoshiyuki Shibata, MD, Surgeon, Department of Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, 3-1 Aoyama, Kure, Hiroshima 737-0023, Japan. yshibata.hiroshima@gmail.com
Received: April 21, 2024
Revised: May 23, 2024
Accepted: June 25, 2024
Published online: August 27, 2024
Processing time: 117 Days and 9.2 Hours
Revised: May 23, 2024
Accepted: June 25, 2024
Published online: August 27, 2024
Processing time: 117 Days and 9.2 Hours
Core Tip
Core Tip: Transmembrane serine protease 4 (TMPRSS4) expression correlates with poor prognosis in patients with biliary tract cancer post-radical resection, indicating its potential as a prognostic biomarker. TMPRSS4 positivity is linked to higher preoperative carbohydrate antigen 19-9 levels, lymphatic invasion, and larger tumor size. This study underscores the importance of TMPRSS4 in enhancing prognostic assessment and guiding treatment strategies for patients with biliary tract cancer undergoing radical resection.